| ATD |
|
asphixiating thoracic dystrophy (chondroectodermal dysplasia-like syndrome)
|
|
|
0.656 |
0.731 |
| FPR1 |
P21462
|
formyl peptide receptor 1
|
G-protein coupled receptor
|
|
0.576 |
0.769 |
| IFNA1 |
P01562
|
interferon alpha 1
|
|
|
0.371 |
0.923 |
| IFNA13 |
P01562
|
interferon alpha 13
|
|
|
0.374 |
0.923 |
| MMP12 |
P39900
|
matrix metallopeptidase 12
|
Enzyme
|
|
0.484 |
0.885 |
| COX1 |
P00395
|
cytochrome c oxidase subunit I
|
Enzyme
|
|
0.441 |
0.885 |
| COX2 |
P00403
|
cytochrome c oxidase subunit II
|
Enzyme
|
|
0.352 |
0.962 |
| THAS |
|
thoracoabdominal syndrome
|
|
|
0.560 |
0.808 |
| PART1 |
|
prostate androgen-regulated transcript 1
|
|
|
0.483 |
0.885 |
| PPP1R2C |
O14990
|
PPP1R2C family member C
|
Enzyme modulator
|
|
0.478 |
0.846 |
| PWAR1 |
|
Prader Willi/Angelman region RNA 1
|
|
|
0.490 |
0.769 |
| COPD |
|
Pulmonary disease, chronic obstructive, severe early-onset
|
|
|
0.456 |
0.885 |
| MIR155 |
|
microRNA 155
|
|
|
0.384 |
0.885 |
| MIR21 |
|
microRNA 21
|
|
|
0.363 |
0.846 |
| PLF |
|
Pulmonary function
|
|
|
0.544 |
0.731 |
| MIR542 |
|
microRNA 542
|
|
|
0.592 |
0.538 |
| P2RX5-TAX1BP3 |
|
P2RX5-TAX1BP3 readthrough (NMD candidate)
|
|
|
0.588 |
0.769 |
| CBSL |
P0DN79 P35520
|
cystathionine beta-synthase like
|
|
|
0.540 |
0.808 |
| MTCO2P12 |
|
MT-CO2 pseudogene 12
|
|
|
0.368 |
0.962 |
| H3P10 |
|
H3 histone pseudogene 10
|
|
|
0.350 |
0.846 |
| MUC16 |
Q8WXI7
|
mucin 16, cell surface associated
|
|
8.3E-112 |
0.479 |
0.808 |
| ROS1 |
P08922
|
ROS proto-oncogene 1, receptor tyrosine kinase
|
Kinase
|
1.6E-72 |
0.439 |
0.885 |
| DNAH5 |
Q8TE73
|
dynein axonemal heavy chain 5
|
Enzyme
|
4.9E-64 |
0.590 |
0.692 |
| CFTR |
P13569
|
CF transmembrane conductance regulator
|
Ion channel
|
2.2E-58 |
0.424 |
0.885 |
| ABCA4 |
P78363
|
ATP binding cassette subfamily A member 4
|
Transporter
|
5.3E-48 |
0.493 |
0.769 |